{{PANUMCODE}}

Tafinlar

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}} **Date**: {{TODAY}}
Patient's ID {{MEMBERID}} **Patient's Date of Birth:** {{MEMBERDOB}}
Physician's Name: {{PHYFIRST}} {{PHYLAST}}
Specialty: ________________________________, **NPI#:** __________________________
Physician Office Telephone: {{PHYSICIANPHONE}} **Physician Office Fax:** {{PHYSICIANFAX}}
Request Initiated For: {{DRUGNAME}}

1. What is the patient's diagnosis?
   ❑ Melanoma BRAF V600 activating mutation-positive
   ❑ Non-small cell lung cancer, BRAF V600E mutation-positive
   ❑ Anaplastic thyroid cancer (ATC), BRAF V600E mutation-positive
   ❑ Glioma, BRAF V600 mutation-positive
   ❑ Meningioma, BRAF V600 mutation-positive
   ❑ Astrocytoma, BRAF V600 mutation-positive
   ❑ Follicular thyroid carcinoma, BRAF mutation positive
   ❑ Hurthle cell thyroid carcinoma, BRAF mutation positive
   ❑ Papillary thyroid carcinoma, BRAF mutation positive
   ❑ Colorectal cancer, BRAF V600E mutation positive
   ❑ Other _____________________________________
2. What is the ICD-10 code? _____________
3. Is this a request for continuation of therapy with the requested drug? ❑ Yes ❑ No *If No, skip to #7*
4. Is there evidence of unacceptable toxicity or disease progression on the current regimen? ❑ Yes ❑ No
5. Is this request for the adjuvant treatment of cutaneous melanoma? ❑ Yes ❑ No *If No, no further questions*
6. Has the patient received 12 months of therapy? ❑ Yes ❑ No *No further questions*
7. What is the patient's mutation status? ***ACTION REQUIRED: Please attach documentation of mutation status.***
   ❑ BRAF V6000 positive ❑ BRAF V6000 negative
   ❑ BRAF V600E positive ❑ BRAF V600E negative
   ❑ Unknown or not available
8. How will the medication be given? ***Indicate ALL that apply.***
   ❑ As a single agent ❑ As subsequent therapy
   ❑ In combination with Mekinist (trametinib)
   ❑ In combination with Mekinist (trametinib) and either cetuximab or panitumumab
   ❑ None of the above

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Melanoma

9. What is the intent of treatment?
   - ❑ Adjuvant treatment of cutaneous melanoma
   - ❑ Treatment of unresectable metastatic cutaneous melanoma*, no further questions*
   - ❑ Treatment of brain metastases from melanoma*, no further questions*
   - ❑ None of the above
10. Will the patient be using the requested medication following complete lymph node dissection/resection or recurrence? ❑ Yes ❑ No

Section B: Non-Small Cell Lung Cancer

11. Does the patient have recurrent, advanced, or metastatic disease? ❑ Yes ❑ No

Section C: Thyroid Carcinoma

11. Is the disease progressive and/or symptomatic? ❑ Yes ❑ No

12. Is the disease iodine-refractory? ❑ Yes ❑ No

Section D: Colorectal Cancer

13. Is the disease unresectable advanced or metastatic? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tafinlar SGM - 6/2020.